Thanks to funding from Proposition 71, California’s $3 billion investment in stem cell research, and the state funding entity it created, the California Institute for Regenerative Medicine (CIRM), there are now 36 human clinical trials in various stages of progress, including a trial for spinal cord injury.

Condition: Glioblastoma

Accepting Applicants: Yes
Status: Phase 3 trial in progress

Description: Clinical trial of stem cell gene therapy for glioblastoma.
CIRM Funding Brief: “This team is targeting six cell surface proteins that are found on cancer stem cells in the brain cancer glioblastoma. Cells from the patient’s own immune system are exposed to fragments of these cancer cell surface proteins in the lab. When returned to the patient’s body, the immune system cells can now help identify and then hopefully kill the cancer stem cells responsible for the tumor’s recurrence and growth.” Read more at CIRM.
Current Sponsor: ImmunoCellular Therapeutics, Ltd.
Principal Investigator: N/A
Institution: N/A
Phase 1/2 Filed: N/A
Phase 1/2 Approved: N/A
Cell Therapy Type: N/A
NCT No. / Link: NCT02546102
Completion Date: Projected December 2021

Last Updated: April 4, 2017

As this clinical trial moves forward, we will update this page. Check back here for future developments.

As scientists and patient advocates build on the progress that Proposition 71 has enabled, we must keep the momentum going, understanding that there is still much work to be done. We must remember that human trials will celebrate successes; but, barriers will surface, along with complications and challenges, so patience and understanding of the scientific discovery process is essential. Even the setbacks will provide critical knowledge that will bring us closer to curing or mitigating devastating diseases and injuries. Only with continued support for biomedical research can we increase our understanding of the therapeutic potential of stem cells, and translate that understanding into meaningful treatments that help give patients their lives back.